In a double-blind , parallel group , phase @/@ trial , participants were randomly assigned with permuted blocks in a @:@ ratio to davunetide ( @ mg twice daily , intranasally ) or placebo for @ weeks at @ centres in Australia , Canada , France , Germany , the UK , and the USA .